BASF sweetens its Evonik takeover bid — collect the takeover spread
An increased bid is a strong signal the buyer is determined to close the deal, which raises the probability the transaction completes near the new offer level. Evonik's shares typically close the gap to the raised offer as the deal progresses, letting traders capture the remaining discount. Unlike directional stock bets, this trade's main risk is deal failure, not market direction — making it largely independent of the tech selloff and Gulf tensions rattling broader markets. The widening premium also suggests BASF may face little rival competition, supporting a clean path to completion.
Idea
An increased bid is a strong signal the buyer is determined to close the deal, which raises the probability the transaction completes near the new offer level. Evonik's shares typically close the gap to the raised offer as the deal progresses, letting traders capture the remaining discount. Unlike directional stock bets, this trade's main risk is deal failure, not market direction — making it largely independent of the tech selloff and Gulf tensions rattling broader markets. The widening premium also suggests BASF may face little rival competition, supporting a clean path to completion.
Advanced Analysis — institutional-depth research report
Verdict: a credible deal thesis with no tradable way to express it — wait
The verdict on this merger-arbitrage idea is wait: the long-term logic that a raised bid raises completion odds near the offer level is plausible, but none of the evidence supplied lets the trade be taken or even measured. The strongest point for the thesis is the over-€11B raised offer itself (per Bloomberg, October 23, 2026) — a buyer rarely raises to that size unless it intends to close — backed by acquirer revenue up 7.4% quarter over quarter to €17.2B and operating cash flow swinging to positive €524M in Q2 2026. The strongest point against is structural: the idea is about Evonik shares, but EVK.DE could not be mapped to a supported instrument, so only the acquirer's ADR (BASFY) is covered, and the compiled entry rule is a deliberate stand-aside with zero triggers over the last 3 months. Meanwhile BASF's free cash flow was still negative at -€189M in Q2 2026, debt-to-equity sits near 0.69 after four years of climbing, and no offer price or deal timeline was supplied, so the discount-to-offer — the entire edge — is simply unknown. The verdict flips the moment a confirmed offer level, acceptance thresholds, closing timeline, and a tradable Evonik instrument arrive together; regulatory pushback, a competing bid, or continued negative free cash flow would instead deepen the avoid posture.
Trade now
Avoid acting on this setup today. The thesis is a merger-arbitrage bet on Evonik (EVK.DE) shares converging toward BASF's raised offer — the idea argues the increased bid signals determination and that the target's discount should close as the deal progresses. But the compiled strategy could only map BASF's US-listed ADR (BASFY), not the Evonik shares the thesis is actually about. The entry rule was therefore set to an intentionally untradable condition (a close below zero), which is a deliberate stand-aside, not a sign the strategy misfired. On BASFY itself, the price closed at $14.72 (as of the October 24 evaluation), sitting just below its 50-day average of $14.89, and up nearly 23% from its range low — nowhere near the deep-discount state a merger arb entry would require on the acquirer's own stock. Separate the two questions. Is the business thesis attractive? Plausibly — a raised bid does raise completion odds near the offer level, per the idea's own argument, and BASF's fundamentals are stable: Q2 2026 revenue of €17.2B (up 7.4% quarter over quarter), net income of €4.1B, a 24.1% net margin, though free cash flow was still negative at -€189M and the dividend has been cut over time (from $0.98/share in 2021 to $0.65 declared for 2026). Are today's entry conditions met? No. The tradable instrument doesn't express the thesis, and no offer price or timeline for the Evonik transaction was supplied, so we cannot compute the discount-to-offer or expected spread — those figures are simply unknown here. "Waiting" concretely means: wait until the target's shares are available as a tradable instrument and until a confirmed offer level and deal timeline let the spread be measured. The downside that matters is deal failure — a complete collapse would drop Evonik shares back toward standalone value, and on BASFY specifically the trailing 12-month drawdown reached 26.3%. One measurement limitation worth stating once: historical performance for BASFY was not measured because its raw and adjusted price series use different bases, so there is no historical performance evidence for this rule set on this instrument. ### Technical details The entry rule (Long Entry, BASFY daily) requires the daily close to be below 0.0 — an untradable constant reflecting the intentional stand-aside. At the last evaluation (October 24), BASFY closed at $14.72, $14.72 above the trigger, so the rule is marked far from triggering. That is by design per the research decision record: the thesis concerns Evonik's shares, which could not be mapped to a supported instrument, so the acquirer's ADR was retained only as the data series with a deliberate avoid posture. The exits that would apply if a position ever existed: a 2.0% stop loss, a 4.0% take profit, a 90-bar time exit, plus level-based exits (take profit at the first resistance level, stop on crossing above the first/second support levels). Current observed levels: nearest resistance $14.73 and $14.98, nearest support $14.82 (noting the level list shows support above the last close, an inverted ordering worth treating cautiously), with the 50-day average at $14.89 and 200-day average at $14.51. RSI (14) — a 0–100 momentum gauge where readings near 50 are neutral — stood at 50.3. None of these constitute an entry signal.
A Determined Buyer With Improving Operating Numbers
The thesis — that BASF's raised, over-€11B bid for Evonik (per Bloomberg, Oct 23, 2026) signals deal determination and lets traders capture the remaining spread in Evonik shares — has real support in BASF's latest reported numbers, though it is a watch-list setup: the entry rules did not trigger in the evaluated window, and the target's shares (EVK.DE) could not be mapped to a supported instrument, so any arb execution would have to happen outside the series covered here. ### A raised bid is a costly, credible signal A buyer does not raise an offer to over €11B (per Bloomberg) unless it intends to close. In merger arbitrage — buying the target below the offer price and pocketing the gap if the deal completes — the seller's discount is compensation for completion risk, so a raised bid mechanically raises the probability-weighted value of the target. The thesis's claim of limited rival competition is consistent with a widening premium: bidding against yourself usually means nobody else is bidding. ### Revenue is re-accelerating into the offer BASF's quarterly revenue rose 7.4% quarter over quarter to €17.21B in Q2 2026 (period ended June 30) from €16.02B in Q1, and is up from €14.79B in Q2 2025 — the strongest quarterly top line in the covered series after the FY2022 peak. For the acquirer, a recovering top line improves the debt capacity and earnings base that must absorb the acquisition, which supports deal feasibility. ### Reported profitability inflected sharply Q2 2026 net income of €4.14B (a 24.1% net margin) is up 347% from €927M in Q1, and return on equity jumped from 2.7% to 11.4%. Interpretation caveat: a jump of that size against…
Scores
- Conviction score breakdown: 34
- Thesis support: 55
- Trade readiness: 15
- Risk quality: 40
- Trigger proximity: 10
- Fundamentals trend: 50
Watch items
- EVK.DE — Discount to confirmed BASF offer price
- EVK.DE — Deal status / regulatory and shareholder approvals
- BASFY — Price vs 200-day average (SMA 200)
- BASFY — RSI (14) momentum
- BASFY — Free cash flow (quarterly, EUR)